Coadministration of a Tumor-Penetrating Peptide Enhances the Efficacy of Cancer Drugs
Has this study been replicated?
The atlas records 1 replication of this study. Recorded outcomes: 1 failed. The earliest on record is from 2017.
Replications
- Replication Study: Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs, Mantis et al. (2017). eLife. Outcome recorded: failed.
we found that coadministration with iRGD peptide did not have an impact on permeability of the chemotherapeutic agent doxorubicin (DOX)
Outcome read from the abstract. View paper
Cite this record
Sugahara, K. N., Teesalu, T., Karmali, P. P., Kotamraju, V. R., Agemy, L., Greenwald, D. R., & Ruoslahti, E. (2010). Coadministration of a Tumor-Penetrating Peptide Enhances the Efficacy of Cancer Drugs. Science, 328(5981), 1031–1035. https://doi.org/10.1126/science.1183057
Other studies in the atlas
Failed replications · Successful replications · All browse pages